The FDA is still on track to meet its user fee targets despite a higher-than-normal vacancy rate among scientific reviewers.

In 2024, HR leaders faced unprecedented pressure from senior executives concerned about continually rising healthcare costs.

Sarepta Therapeutics is refusing to pull its gene therapy Elevidys (delandistrogene moxeparvovec), despite a request from the FDA.

The American Benefits Council is urging Congress to consider the cost to employers, workers and their families as it proposes ...

Moses reported same-store growth of 8.6% in the CCRC business, driven by rate growth of 5% and higher entrance fee sales. Outpatient medical achieved 85% tenant retention, a positive rent ...

The number of Americans caring for an older or disabled family member has risen dramatically during the past 10 years, ...

While shoplifting gets more attention, retailers should focus on employee theft, which can account for 55% of losses on ...

Pharmacists say insurance reimbursements fail to cover their costs. They say a new law isn’t enough to reverse the trend.

As the second Trump Administration concludes its sixth month, the U.S. Department of Justice has identified its top False ...

Welcome to our live blog tracking the latest news and developments from the United States. Stay updated with real-time ...

It’s the epicenter. ... it’s literally our everything. It is our business district, that darn Fred Meyer, right there,” the ...

People experiencing homelessness in the Wilkes-Barre area are having a harder time coping with life on the street since Keystone Mission closed its overnight and daytime drop-in shelter two weeks ...